MA28228A1 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation - Google Patents

Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation

Info

Publication number
MA28228A1
MA28228A1 MA29103A MA29103A MA28228A1 MA 28228 A1 MA28228 A1 MA 28228A1 MA 29103 A MA29103 A MA 29103A MA 29103 A MA29103 A MA 29103A MA 28228 A1 MA28228 A1 MA 28228A1
Authority
MA
Morocco
Prior art keywords
benzisoxazoles
indazoles
preparation
indoles
compounds
Prior art date
Application number
MA29103A
Other languages
English (en)
Inventor
Wenge Xie
Brian Herbert
Jianguo Ma
Truc Minh Nguyen
Richard A Schumacher
Carla-Maria Gauss
Ashok Tehim
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of MA28228A1 publication Critical patent/MA28228A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La présente invention concerne de manière générale, le domaine des ligands pour les récepteurs nicotiniques de l'acétylcholine (nAChR), l'activation des nAChR et le traitement de maladies associées à un défaut ou un dysfonctionnement des récepteurs nicotiniques de l'acétylcholine, en particulier dans le cerveau. De plus, l'invention concerne de nouveaux composés, par exemple des indoles, des lH-indazoles, des 1,2-benzisoxazoles et des 1,2-benisothiazoles, qui agissent comme ligand du sous-type (alpha)7 de nAChR, des procédés de préparation de ces composés, des compositions contenant ces composés et des procédés d'utilisation de ceux-ci.
MA29103A 2003-12-22 2006-06-14 Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation MA28228A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53089103P 2003-12-22 2003-12-22
US60689704P 2004-09-03 2004-09-03

Publications (1)

Publication Number Publication Date
MA28228A1 true MA28228A1 (fr) 2006-10-02

Family

ID=34742980

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29103A MA28228A1 (fr) 2003-12-22 2006-06-14 Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation

Country Status (22)

Country Link
US (4) US7396833B2 (fr)
EP (1) EP1697378B1 (fr)
JP (1) JP4824578B2 (fr)
KR (1) KR20060120694A (fr)
AU (1) AU2004309367B2 (fr)
BR (1) BRPI0417323A (fr)
CA (1) CA2550689A1 (fr)
CR (1) CR8472A (fr)
DE (1) DE602004010299T2 (fr)
DK (1) DK1697378T3 (fr)
EC (1) ECSP066669A (fr)
ES (1) ES2295973T3 (fr)
IL (1) IL176283A0 (fr)
MA (1) MA28228A1 (fr)
NO (1) NO20063392L (fr)
NZ (1) NZ548228A (fr)
PL (1) PL1697378T3 (fr)
PT (1) PT1697378E (fr)
RS (1) RS20060391A (fr)
RU (1) RU2389729C2 (fr)
SG (1) SG149830A1 (fr)
WO (1) WO2005063767A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (fr) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
WO2006089168A2 (fr) * 2005-02-18 2006-08-24 Cornell Research Foundation, Inc. Procede pour moduler des canaux ioniques
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
CN101312968A (zh) * 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
CN101316849A (zh) * 2005-11-09 2008-12-03 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮及其制备和用途
MX2008012952A (es) * 2006-04-11 2008-10-15 Hoffmann La Roche Moduladores heterociclicos del receptor selectivo del subtipo alfa de gaba.
EP2046753A2 (fr) * 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
BRPI0920187A2 (pt) 2008-10-13 2019-08-27 Hoffmann La Roche método sem diazônio para fabricar um indazol intermediário na síntese de amidas bicíclicas do ácido 5-(triflúor-metóxi)-1h-3-indazol-carboxílico
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2011044506A2 (fr) 2009-10-09 2011-04-14 Zafgen Corporation Composés sulfonés et leurs procédés de fabrication et d'utilisation
MX2012006484A (es) * 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
WO2011085389A1 (fr) * 2010-01-11 2011-07-14 Astraea Therapeutics, Llc Modulateurs du récepteur nicotinique de l'acétylcholine
US20110172428A1 (en) 2010-01-12 2011-07-14 Shan-Ming Kuang Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
US8242276B2 (en) 2010-06-30 2012-08-14 Hoffmann-La Roche Inc. Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt
WO2012012642A1 (fr) 2010-07-22 2012-01-26 Zafgen Corporation Composés tricycliques et procédés pour les préparer et les utiliser
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
MX344910B (es) 2011-12-23 2017-01-11 Basf Se Proceso para la manufactura de ariloxiacetamidas.
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
RU2014144951A (ru) * 2012-04-10 2016-06-10 Сумитомо Дайниппон Фарма Ко., Лтд. Новое 1-замещенное производное индазола
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
CA2890342A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques et procedes de fabrication et d'utilisation associes
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CA2905242C (fr) 2013-03-15 2016-11-29 Pfizer Inc. Composes indoliques activant l'ampk
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
US10231970B2 (en) 2014-09-30 2019-03-19 NV Heterocycles Methods of producing heteropolycycles via bis-epoxidation
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法
CA3200439A1 (fr) * 2020-12-08 2022-06-16 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 a base de benzopyrazole

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2548666A1 (fr) 1983-07-08 1985-01-11 Delalande Sa Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
WO1985001048A1 (fr) 1983-08-26 1985-03-14 Sandoz Ag Esters ou amides aromatiques de l'acide carbonique et de l'acide sulfonique
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
GB8623142D0 (en) 1986-09-26 1986-10-29 Beecham Group Plc Compounds
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5204356A (en) * 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
IN166416B (fr) * 1985-09-18 1990-05-05 Pfizer
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0340270B1 (fr) * 1987-11-14 1992-07-15 Beecham Group Plc Antagonistes recepteurs 5-ht 3? de traitement de la toux et de la bronchoconstriction
US4950759A (en) * 1988-07-07 1990-08-21 Duphar International Research B.V. Substituted 1,7-annelated 1H-indazoles
US4895943A (en) * 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5223625A (en) * 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (fr) 1988-12-22 1990-07-11 Duphar International Research B.V Indolo(3,2-c)-lactames annelés
WO1990014347A1 (fr) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament
US5446050A (en) * 1989-11-17 1995-08-29 Pfizer Inc. Azabicyclo amides and esters as 5-HT3 receptor antagonists
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
JPH06506443A (ja) 1991-01-09 1994-07-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
AU658194B2 (en) * 1991-03-28 1995-04-06 Eisai Co. Ltd. Heterocyclic-cyclic amine derivatives
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US5273972A (en) * 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
IT1256623B (it) * 1992-12-04 1995-12-12 Federico Arcamone Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
CA2361525C (fr) * 1999-01-29 2009-12-08 Abbott Laboratories Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6845001B1 (en) 1999-07-12 2005-01-18 Mitsubishi Denki Kabushiki Kaisha Electromagnetic contactor
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
CA2409644A1 (fr) 2000-05-25 2001-11-29 Targacept, Inc. Heteroaryldiazabicycloalkanes comme ligands du recepteur cholinergique nicotinique
FR2809732B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) * 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002036114A1 (fr) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprenant les antagonistes des recepteurs de serotonine 5 ht-2 et 5 ht-3
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
EP1397365B1 (fr) * 2001-06-01 2005-02-16 NeuroSearch A/S Heteroaryl-diazabicyclo-alcanes a titre de modulateurs du snc
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
BR0212477A (pt) 2001-09-12 2004-08-24 Upjohn Co 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
MXPA04003007A (es) 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
US6849620B2 (en) * 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
WO2003037896A1 (fr) 2001-10-26 2003-05-08 Pharmacia & Upjohn Company Carboxamides hetero-bicycliques substitues par n-azabicyclo, utilises en tant qu'agonistes du recepteur de l'acetylcholine nicotinique
WO2003042210A1 (fr) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Composes heterocycliques fusionnes avec un groupe phenyl-azabicyclique et leur utilisation en tant que ligands de recepteur nachr alpha 7
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10305922A1 (de) 2002-06-10 2004-03-04 Bayer Ag 2-Heteroarylcarbonsäureamide
JP3985139B2 (ja) 2002-02-06 2007-10-03 日本ゼオン株式会社 変性重合体およびコーティング材
WO2003070731A2 (fr) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Composes azabicycliques servant a traiter des maladies
EP1478646A1 (fr) 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Composes azabicycliques presentant une activite de recepteurs d'alfa 7 nicotinique acetylcholine
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2197001B1 (es) 2002-03-26 2004-11-16 Laboratorios Vita, S.A. Procedimiento de obtencion de un compuesto farmaceuticamente activo.
CN100522976C (zh) 2002-05-07 2009-08-05 神经研究公司 氮杂环乙炔基衍生物
MXPA04011858A (es) 2002-05-30 2005-03-31 Neurosearch As Quinuclidinas sustituidas en la posicion 3 y su uso.
ES2276072T3 (es) 2002-06-10 2007-06-16 Bayer Healthcare Ag Amidas de acidos 2-heteroarilcarboxilicos.
EP1546156A1 (fr) 2002-08-10 2005-06-29 Astex Technology Limited Composes 3-(carbonyl) 1h-indazole utilises en tant qu'inhibiteurs de kinases cycline-dependantes (cdk)
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
US7456171B2 (en) * 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
US6945618B2 (en) 2003-06-02 2005-09-20 Accuride International Inc. Drawer slide adjustment mechanism
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
JP2005230084A (ja) 2004-02-17 2005-09-02 Olympus Corp バルーン取付け治具
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用

Also Published As

Publication number Publication date
CR8472A (es) 2007-09-07
IL176283A0 (en) 2006-10-05
WO2005063767A2 (fr) 2005-07-14
US7396833B2 (en) 2008-07-08
NO20063392L (no) 2006-09-21
EP1697378B1 (fr) 2007-11-21
US8158629B2 (en) 2012-04-17
CA2550689A1 (fr) 2005-07-14
JP4824578B2 (ja) 2011-11-30
PL1697378T3 (pl) 2008-04-30
AU2004309367A1 (en) 2005-07-14
NZ548228A (en) 2009-04-30
AU2004309367B2 (en) 2010-04-01
US20050176754A1 (en) 2005-08-11
DE602004010299D1 (de) 2008-01-03
RU2389729C2 (ru) 2010-05-20
US7964600B2 (en) 2011-06-21
DK1697378T3 (da) 2008-03-17
US20110312989A1 (en) 2011-12-22
RS20060391A (sr) 2008-11-28
US7790722B2 (en) 2010-09-07
BRPI0417323A (pt) 2007-03-27
US20090088437A1 (en) 2009-04-02
WO2005063767A3 (fr) 2005-08-25
JP2007515424A (ja) 2007-06-14
US20110028483A1 (en) 2011-02-03
PT1697378E (pt) 2008-02-28
EP1697378A2 (fr) 2006-09-06
RU2006126540A (ru) 2008-01-27
DE602004010299T2 (de) 2008-09-18
ES2295973T3 (es) 2008-04-16
KR20060120694A (ko) 2006-11-27
ECSP066669A (es) 2006-10-25
SG149830A1 (en) 2009-02-27

Similar Documents

Publication Publication Date Title
MA28228A1 (fr) Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
MA27453A1 (fr) Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations
MA28972B1 (fr) Indazoles, benzothiazoles , benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
ATE503754T1 (de) 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
DE602005024677D1 (de) Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
TNSN06188A1 (fr) Derives de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de recepteurs de chimiokines
MA30999B1 (fr) Composés.
MA24729A1 (fr) Macrolides nouveaux.
TNSN07071A1 (fr) Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases
MA27794A1 (fr) Dihydroquinazolines substituees a proprietes antivirales
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
AP1503A (en) Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
TN2009000551A1 (fr) Nouveaux composes chimiques
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
TNSN07167A1 (fr) Indoles substitues, compositions les contenant, procede de fabrication et utilisation
MA30027B1 (fr) [ (1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes utilises en tant que ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
AU4038600A (en) 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands